Fondaparinux sodium.
1 Inquiries
114870-03-0
Shanghai
100g/bag
Yes
2025-04-24
13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceFondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
Fondaparinux Sodium is the sodium salt form of fondaparinux, a synthetic glucopyranoside with antithrombotic activity. Fondaparinux sodium selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. (NCI05)|Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.
Fondaparinux sodium was first introduced in the US for prophylaxis of deep vein thrombosis which may lead to pulmonary embolism following major orthopaedic surgery. Fondaparinux is the first of a new class of antithrombic agents distinct from low molecular weight heparin (LMWH) and heparin. This entirely synthetic molecule is a copy of the heparin pentasaccharide sequence, the shortest fragment able to catalyze antithrombin lllmediated inhibition of factor Xa thereby inhibiting thrombin generation without antithrombin action. Fondaparinux does not display significant effects on coagulation tests (such as activated partial thromboplastin time and prothrombin time), does not bind to platelet factor 4 or promote heparin-induced thrombocytopenia. In phase III studies, fondaparinux significantly reduced the incidence of thromboembolism following orthopedic surgery, with an overall risk reduction of 50% in comparison to the LMWH, enoxaparin. Following subcutaneous administration, fondaparinux has a nearly complete bioavailability, a rapid onset of action, a prolonged half-life (17.2 h) enabling once daily dosing and is not metabolized preceeding renal excretion. The drug appears to be generally safe, with haemoragic complications either comparable to or higher than those for LMWH.
White Powder (after lyophilisation)
ChEBI: An organic sodium salt, being the decasodium salt of fondaparinux.Basic Info-
Product Name:
Fondaparinux sodium
Other Name:Fondaparin SodiuM;Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoaMino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoaMino)-α-D-glucopyranoside 6-(Hydrogen Sulfate) DecasodiuM Salt;Fondaparinux SodiuM Identification;Methyl O-2-Deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-β- D-glucopyranuronosyl-(14)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(14)-O-2-O-sulfo-α-L-idopyranuronosyl-(14)-2-deoxy-2-(sulfoamino)-α-D-glucopyra;Fondaparinux sodium N-4;Fondaparinux sodium, >=98%;decasodium 6-[[6-[[2-carboxylato-4-hydroxy-6-[[4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)-3-oxanyl]oxy]-5-sulfonatooxy-3-oxanyl]oxy]-5-(sulfonatoamino)-4-sulfonatooxy-2-(sulfonatoox;decasodium (2R,3S,4S,5R,6R)-3-[(2R,3R,4R,6R)-5-[(2R,3R,4S,5S,6S)-6-carboxylato-5-[(2R,3R,4R,5S,6R)-4,5-dihydroxy-3-(sulfonatoamino)-6-(sulfonatooxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-oxan-2-yl]oxy-3-(sulfonatoamino)-4-sulfonatooxy-6-(sulfonatooxymethyl)oxan-2-yl]oxy-4-hydroxy-6-[(2R,3S,4R,5R,6S)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxy-oxane-2-carboxylate
CAS No.:114870-03-0
Molecular Formula:C31H43N3O49S8.10Na
InChIKeys:XEKSTYNIJLDDAZ-UWCYYFDCNA-D
Molecular Weight:1728.08
Exact Mass:1726.770777
EC Number:686-283-7
UNII:X0Q6N9USOZ
NCI Thesaurus Code:C47539
Color/Form:White to Off-White
ATC Code:B01AX05
HScode:3822000002
Categories:
Characteristics-
PSA:
901
Melting Point:>209°C (dec.)
Specific rotation:D23 +48° (c = 0.61 in water)
Critical Temperature & Pressure:2-8°C
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Inhalation
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H332 Harmful if inhaled
Precautionary statement(s) Prevention P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
Response P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P317 Get medical help.
Storage none
Disposal none
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
13-Dimethyladamantane,1-Bromo-35-dimethyladamantane,perhydroacenaphthylene,4-[1,1-bis(4-hydroxyphenyl)ethyl]phenol,CYCLOBUTANE-1
-
Location:
Room 1623,Building A, ZhongqiaoCenter,Goverment District,Hefei city,Anhui Province,China
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
5-10
-
Year of Establishment:
2019
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted 
Austria
Fondaparinux sodium
100 MG Mar 21, 2025 Post an enquiry for this product
